CClinicalTrials.gg
CompletedNCT04810221SOMBREROUpdated Apr 20, 2022Results posted

Postmarket Clinical Follow-up Study to Confirm the Performance of the Wearable Pulse-Oximeter BrOxy M (SOMBRERO)

An interventional study of Controlled desaturation study in Laboratory Testing on Healthy Volunteers to Verify SpO2 and Heart Rate (HR) Accuracy of BrOxy M, sponsored by Life Meter srl. Completed at 1 site in Italy. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-20.

Sponsored by Life Meter srl · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study is a post market clinical follow up study performed to confirm the performance of BrOxy M pulse oximeter in comparison with a reference, CE marked, pulse oximeter equipment in a controlled desaturation study over a range between 80% and 100% peripheral oxygen saturation (SpO2).

The study will be performed on a group of healthy volunteers in a controlled clinical setting.

Read the detailed description

This study is a post market clinical follow up study performed to confirm the performance of BrOxy M pulse oximeter in comparison with a reference, CE marked, pulse oximeter equipment (Nellcor™ Bedside Respiratory Patient Monitoring System model PM1000N, Covidien LLC, USA) in a controlled desaturation study over a range between 80% and 100% SpO2.

The study will be performed on a group of healthy volunteers in a controlled clinical setting. Due to the use of a controlled desaturation protocol foreseen by the standard ISO 80601-2-61:2017, this study is classified as an interventional post-market clinical study in accordance with Annex I of EN ISO 14155:2020.

02

Conditions studied

  • Laboratory Testing on Healthy Volunteers to Verify SpO2 and Heart Rate (HR) Accuracy of BrOxy M
03

In context

Lead sponsor

This is the only study on the registry with Life Meter srl as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Healthy subjects of both sexes with an age ≥ 18 and ≤ 50.
  2. American Society of Anesthesiology (ASA) classification 1
  3. Positive Allen's test
  4. Intact and healthy skin on the selected wrist
  5. Wrist circumference diameter between 150 mm e 200 mm.
  6. Normal electrocardiogram (ECG) obtained at screening or within 2 months prior to screening
  7. Ability to understand and execute the required study procedures and provide an informed consent to the study

Exclusion criteria

Exclusion Criteria:

  1. Presence of at least one of the following altered hemoglobin parameters at screening:

    1. Alpha-hemoglobin (αHb) ≤ 10 gr/dl
    2. Carboxy-hemoglobin (COHb) ≥ 3%
    3. Methaemoglobin (MetHb) ≥ 2%
  2. For pre-menopausal female subjects only: positive pregnancy test performed at screening on urines or capillary blood
  3. Presence of any cardiovascular pathology in medical history.
  4. Any episodes of respiratory infection during the 30 days prior to screening
  5. Any prior experience of Dyspnea
  6. Hospitalization during the 2 months prior to screening, for any reason.
  7. Chronic drug intake known to interfere with gaseous exchanges or induce changes in cardiac frequency
  8. Presence of any medical condition not allowing the subject to perform the required test
  9. Known allergy to adhesive tapes
  10. Participation in an interventional study with a medicinal product or a medical device in the 30 days prior to screening.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Experimental

    Measure of SpO2 and HR obtained in enrolled subjects using BrOxy M and a reference pulse oximeter in paired observations

    Other: Controlled desaturation study

Interventions

  • OtherControlled desaturation study

    Measure of SpO2 and Heart Rate by BrOxy M device and reference device in a controlled desaturation study.

06

What researchers measure

Primary outcomes

  1. Accuracy of SpO2 Measurement at 80-100% SpO2

    Accuracy of SpO2 measurements obtained with BrOxy M in comparison with the reference pulse oximeter in paired observations over a range between 80% and 100% SpO2. Based on the standard ISO 80601-2-61:2017, the accuracy is stated in terms of the root-mean-square difference between the readings of the BrOxy M and the standard readings of the reference pulse oximeter.

    Time frame: The measures started around 2 minutes after beginning of the test session and ended around 33 minutes later.

  2. Accuracy of Heart Rate Measurement at 80-100% SpO2

    Accuracy of measurements obtained with BrOxy M with that obtained with the reference pulse oximeter in paired observations. Based on the standard ISO 80601-2-61:2017, the accuracy is stated in terms of the root-mean-square difference between the readings of the BrOxy M and the standard readings of the reference pulse oximeter.

    Time frame: The test started around 2 minutes after beginning of the test session and ended after around 33 minutes.

Secondary outcomes

  1. Agreement Between Broxy M and Reference Device SpO2 Measurements - Cut Off at 94% SpO2

    Cohen's kappa coefficient to evaluate the agreement between Broxy M and the reference device for 94% SpO2 cut off. Cohen's kappa coefficient takes into account the possibility of agreement occurring by chance.

    Time frame: Around 5 min after beginning of the test session

  2. Agreement Between Broxy M and the Reference Device SpO2 Measurements - Cut Off at 90% SpO2

    Cohen's kappa coefficient to evaluate the agreement between Broxy M and the reference device for 90% SpO2 cut off

    Time frame: After around 10 min after beginning of the test session

07

Results

Posted Apr 20, 2022

Participant flow

Participant flow — Overall Study
MilestoneExperimental
Started16
Completed13
Not completed3
Withdrew: Physician decision3

Outcome measures

PrimaryAccuracy of SpO2 Measurement at 80-100% SpO2

Accuracy of SpO2 measurements obtained with BrOxy M in comparison with the reference pulse oximeter in paired observations over a range between 80% and 100% SpO2. Based on the standard ISO 80601-2-61:2017, the accuracy is stated in terms of the root-mean-square difference between the readings of the BrOxy M and the standard readings of the reference pulse oximeter.

Time frame:
The measures started around 2 minutes after beginning of the test session and ended around 33 minutes later.
Reported as:
Mean · A(RMS) - %
Accuracy of SpO2 Measurement at 80-100% SpO2
A(RMS) - %Experimental
Accuracy of SpO2 Measurement at 80-100% SpO22.7 (-5.1 to 5.5)
Statistical analysis
  • Experimental · Paired T-test 0 · p = 0.31 · Mean difference (final values): 0.18 · 95% CI -0.17 to 0.54
PrimaryAccuracy of Heart Rate Measurement at 80-100% SpO2

Accuracy of measurements obtained with BrOxy M with that obtained with the reference pulse oximeter in paired observations. Based on the standard ISO 80601-2-61:2017, the accuracy is stated in terms of the root-mean-square difference between the readings of the BrOxy M and the standard readings of the reference pulse oximeter.

Time frame:
The test started around 2 minutes after beginning of the test session and ended after around 33 minutes.
Reported as:
Mean · bpm
Accuracy of Heart Rate Measurement at 80-100% SpO2
bpmExperimental
Accuracy of Heart Rate Measurement at 80-100% SpO23.7 (-7.1 to 7.7)
Statistical analysis
  • Experimental · Paired T test 0 · p = 0.32 · Mean difference (final values): 0.25 · 95% CI -0.24 to 0.75
SecondaryAgreement Between Broxy M and Reference Device SpO2 Measurements - Cut Off at 94% SpO2

Cohen's kappa coefficient to evaluate the agreement between Broxy M and the reference device for 94% SpO2 cut off. Cohen's kappa coefficient takes into account the possibility of agreement occurring by chance.

Time frame:
Around 5 min after beginning of the test session
Reported as:
Number · Cohen's kappa coefficient
Agreement Between Broxy M and Reference Device SpO2 Measurements - Cut Off at 94% SpO2
Cohen's kappa coefficientExperimental
Agreement Between Broxy M and Reference Device SpO2 Measurements - Cut Off at 94% SpO20.79
SecondaryAgreement Between Broxy M and the Reference Device SpO2 Measurements - Cut Off at 90% SpO2

Cohen's kappa coefficient to evaluate the agreement between Broxy M and the reference device for 90% SpO2 cut off

Time frame:
After around 10 min after beginning of the test session
Reported as:
Number · Cohen's kappa coefficient
Agreement Between Broxy M and the Reference Device SpO2 Measurements - Cut Off at 90% SpO2
Cohen's kappa coefficientExperimental
Agreement Between Broxy M and the Reference Device SpO2 Measurements - Cut Off at 90% SpO20.80

Adverse events

Collected over The reporting period for adverse events was from the day the subject performed screening examinations until study exit (ie around 1-2 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental0/12 (0%)0/12 (0%)0/12 (0%)

Baseline characteristics

SpO2and HR paired measurements were obtained in parallel from the reference device and BrOxy M. The final number of data pairs included in the statistical analyses was 219.

Age, Continuous
Age, Continuous(years)Experimental
Mean37 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Experimental
Female2
Male10
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Experimental
Skin pigmentation
Skin pigmentation(Participants)Experimental
Skin black4
skin white8
Body/Mass Index (BMI)
Body/Mass Index (BMI)(kg/m^2)Experimental
Mean26.2 ± 3.3
08

Study locations

1 site
  • Ospedale "SS. Annunziata"
    Chieti, 66100, Italy
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Dec 22, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04810221
Lead sponsor
Life Meter srl
Responsible party
Sponsor
First posted
Mar 22, 2021
Start date
Mar 24, 2021
Primary completion
Apr 12, 2021
Completion
Apr 12, 2021
Results posted
Apr 20, 2022
Last update
Apr 20, 2022

Study contacts

Stefano Marinari, Medicine
principal investigator · Ospedale "SS. Annunziata", Via dei Vestini, 66100 Chieti, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion